Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Starts Presentation at the 2017 Marcum Microcap Conference
Tonix Pharmaceuticals (NASDAQ: TNXP) is developing innovative pharmaceutical products to address major public health challenges. In addition to TNX-102 SL for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, as a potential smallpox-preventing vaccine. Company executives have a track record of success in drug development, regulatory approvals, and product launch activities. For more information, visit the company's website at www.tonixpharma.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides…







